RxDoctor Payments Data

David Paskil, MD

Family Medicine · Irvine, CANPI 1942228697

Payments from drug & device makers

$662in general payments, 2019–2025

Across 30 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$200
  • Regeneron Healthcare Solutions, Inc.$120
  • Merck$54
  • Pfizer$54
  • Lilly USA, LLC$52
  • Therapeuticsmd, Inc.$35
  • plus $146 from 8 others

What the payments were for

  • Food & beverage$65699%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$662 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$80,781
Medicare patients
297
Services billed
2,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide19$29,833
JanuviaSitagliptin Phosphate15$16,812
EliquisApixaban18$14,619
FarxigaDapagliflozin Propanediol12$11,830
LyricaPregabalin14$11,051
MyrbetriqMirabegron19$10,663
Breo ElliptaFluticasone/Vilanterol14$9,191
SynthroidLevothyroxine Sodium26$3,068
RitalinMethylphenidate Hcl12$2,943
Atorvastatin Calcium316$2,858
Tamsulosin Hcl200$2,746
Diclofenac Sodium141$2,324
Eszopiclone40$2,272
Levothyroxine Sodium160$2,215
ValacyclovirValacyclovir Hcl17$2,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$52$29,83319 claims
PfizerEliquis, Lyrica$54$25,67032 claims
MerckJanuvia$54$16,81215 claims
AstraZenecaFarxiga$200$11,83012 claims
Astellas Pharma US IncMyrbetriq$17$10,66319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →